Bridging therapies to liver transplantation for hepatocellular carcinoma: A bridge to nowhere?

Autor:	Tan CHN; Division of Hepatobiliary and Pancreatic Surgery and Liver Transplantation, Department of Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore.; National University Centre for Organ Transplantation, National University Health System, Singapore, Singapore., Yu Y; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Tan YRN; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Lim BLK; Department of Gastroenterology and Hepatology, National University Health System, Singapore, Singapore.; National University Centre for Organ Transplantation, National University Health System, Singapore, Singapore., Iyer SG; Division of Hepatobiliary and Pancreatic Surgery and Liver Transplantation, Department of Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore.; National University Centre for Organ Transplantation, National University Health System, Singapore, Singapore., Madhavan K; Division of Hepatobiliary and Pancreatic Surgery and Liver Transplantation, Department of Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore.; National University Centre for Organ Transplantation, National University Health System, Singapore, Singapore., Kow AWC; Division of Hepatobiliary and Pancreatic Surgery and Liver Transplantation, Department of Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore.; National University Centre for Organ Transplantation, National University Health System, Singapore, Singapore.
Jazyk:	angličtina
Zdroj:	Annals of hepato-biliary-pancreatic surgery [Ann Hepatobiliary Pancreat Surg] 2018 Feb; Vol. 22 (1), pp. 27-35. Date of Electronic Publication: 2018 Feb 26.
DOI:	10.14701/ahbps.2018.22.1.27
Abstrakt:	Backgrounds/aims: Liver Transplantation (LT) is a recognized treatment for Hepatocellular Carcinoma (HCC). The role of Bridging Therapies (BT) remains controversial. Methods: From January 2001 to October 2012, 192 patients were referred to the National University Hospital, Singapore for consideration of LT for HCC. Sixty-five patients (33.8%) were found suitable for transplant and were placed on the waitlist. Analysis was performed in these patients. Results: The most common etiology of HCC was Hepatitis B (n=28, 43.1%). Thirty-six patients (55.4%) received BT. Seventeen patients (47.2%) received TACE only, while 10 patients (27.8%) received radiofrequency ablation (RFA) only. The remaining patients received a combination of transarterial chemoembolization (TACE) and RFA. Baseline tumor and patient characteristics were comparable between the two groups. The overall dropout rate was 44.4% and 31.0% in the BT and non-BT groups, respectively ( p =0.269). The dropout rate due to disease progression beyond criteria was 6.9% (n=2) in the non-bridged group and 22.2% (n=8) in the bridged group ( p =0.089). Thirty-nine patients (60%) underwent LT, of which all patients who underwent Living Donor LT did not receive BT (n=4, 21.1%, p =0.030). The median time to LT was 180 days (range, 20-558 days) in the non-BT group and 291 days (range, 17-844 days) in the BT group ( p =0.214). There was no difference in survival or recurrence between the BT and non-BT groups ( p =0.862). Conclusions: BT does not influence the dropout rate or survival after LT but it should be considered in patients who are on the waitlist for more than 6 months.
Databáze:	MEDLINE
Externí odkaz: